1,263 reports of this reaction
4.4% of all INSTALAX POLYETHYLENE GLYCOL 3350 reports
#2 most reported adverse reaction
INCORRECT PRODUCT ADMINISTRATION DURATION is the #2 most commonly reported adverse reaction for INSTALAX POLYETHYLENE GLYCOL 3350, manufactured by ANI Pharmaceuticals, Inc.. There are 1,263 FDA adverse event reports linking INSTALAX POLYETHYLENE GLYCOL 3350 to INCORRECT PRODUCT ADMINISTRATION DURATION. This represents approximately 4.4% of all 28,632 adverse event reports for this drug.
Patients taking INSTALAX POLYETHYLENE GLYCOL 3350 who experience incorrect product administration duration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT PRODUCT ADMINISTRATION DURATION is moderately reported among INSTALAX POLYETHYLENE GLYCOL 3350 users, representing a notable but not dominant share of adverse events.
In addition to incorrect product administration duration, the following adverse reactions have been reported for INSTALAX POLYETHYLENE GLYCOL 3350:
The following drugs have also been linked to incorrect product administration duration in FDA adverse event reports:
INCORRECT PRODUCT ADMINISTRATION DURATION has been reported as an adverse event in 1,263 FDA reports for INSTALAX POLYETHYLENE GLYCOL 3350. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT PRODUCT ADMINISTRATION DURATION accounts for approximately 4.4% of all adverse event reports for INSTALAX POLYETHYLENE GLYCOL 3350, making it one of the most commonly reported side effect.
If you experience incorrect product administration duration while taking INSTALAX POLYETHYLENE GLYCOL 3350, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.